Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK 692342 in Adults with TB
NCT01424501Phase 2Terminated
- Sponsor
- GSK
- Start
- Nov 2011
- Primary completion
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of M72 + AS01E in Tuberculosis (TB) (6 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Any and Grade 3 Solicited Local Symptoms, Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms and 2 more. Started Nov 2011; status: terminated.
02
Drugs
M72 + AS01E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01424501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01424501.